EXPRESSION OF SAA1 IN PERIPHERAL BLOOD AND TISSUES OF BREAST CANCER PATIENTS AND ITS VALUE IN EARLY WARNING OF BREAST CANCER

Objective: To explore the expression of SARI in the peripheral blood and tissues of patients with breast cancer and understand its value in the early detection of breast cancer. Methods: From June 2017 to May 2018, 80 patients with breast cancer who underwent surgical resection in our hospital were collected as the observation group, and samples of breast cancer tissue and normal paracancerous tissue were collected during those procedures. Another 50 adults who had a physical examination in our hospital at the same time were collected as the control group. Enzyme-linked immunosorbent assay (ELISA) and fluorescence quantitative PCR were used to detect the levels of serum amyloid A 1 (SAA1) and mRNA expression in all tissues of all participants, and the value of SAA1 in the early detection of breast cancer was analysed by drawing the ROC curve. Results: The level of SAA1 in the observation group was significantly higher than that in the control group (P<0.05). The positive expression rate of SAA1 in breast cancer was 41.25% (33 / 80), which was significantly higher than levels in normal breast tissue. The expression of SAA1 in breast cancer was correlated with tumour size, lymph node metastasis and histological grade (P<0.05), but not with age and clinical stage (P>0.05). Lymph node metastasis and SAA1 expression are independent risk factors for the prognosis of patients with breast cancer. The area under the curve of SAA1 mRNA in plasma and tissue was 0.718 and 0.902, respectively. Conclusion: The changes in the SAR1 level in the course of breast cancer occurrence and development can provide a reference for early detection and the evaluation of clinical treatment and SAA1 can also be an independent risk factor affecting the prognosis of patients with breast cancer, which is of great significance to evaluate the prognosis of patients.